---
title: "Linzess (linaclotide) in irritable bowel syndrome with constipation: Guidelines questions"
description: "Guidelines questions on Linzess (linaclotide) in irritable bowel syndrome with constipation, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Do ACG (2021) and AGA (2022) guidelines recommend Linzess, a GC-C agonist, for adult IBS-C? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/guidelines"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Linzess (linaclotide) in irritable bowel syndrome with constipation: Guidelines questions

Manufacturer: AbbVie, Inc.; Ironwood Pharmaceuticals, Inc.  
Prescribing information: [Linzess](https://www.rxabbvie.com/pdf/linzess_pi.pdf)

Questions that apply to every indication of Linzess are on [Linzess (linaclotide), all indications](https://www.evicenter.com/medical-information/linzess).

## Guidelines

<a id="linzess-guidelines"></a>

### Do ACG (2021) and AGA (2022) guidelines recommend Linzess, a GC-C agonist, for adult IBS-C?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in adults

> “LINZESS, a GC-C agonist, is recommended for the treatment of adult patients with IBS-C<sup>2,3</sup>”

Source: [LINZESS: LINZESS® (linaclotide) Safety Profile Among IBS-C Patients | For HCPs, captured 2026-11-14](https://www.linzesshcp.com/linzess-ibs-c-safety#:~:text=LINZESS%2C%20a%20GC%2DC%20agonist%2C%20is,treatment%20of%20adult%20patients%20with)

> “<sup>†</sup>ACG, a strong recommendation is when most patients should receive the recommended course of action. AGA, for patients, a strong recommendation is when most patients would want the recommended course of action; for HCPs, a strong recommendation is when most patients should receive the intervention. These recommendations are not based on comparative data with other agents.<sup>2,3</sup>”

Source: [LINZESS: LINZESS® (linaclotide) Safety Profile Among IBS-C Patients | For HCPs, captured 2026-11-14](https://www.linzesshcp.com/linzess-ibs-c-safety#:~:text=a%20strong%20recommendation%20is%20when,on%20comparative%20data%20with%20other)

> “2. Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036 3. Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation. Gastroenterology. 2022;163(1):118-136. doi:10.1053/j.gastro.2022.04.016”

Source: [LINZESS: LINZESS® (linaclotide) Safety Profile Among IBS-C Patients | For HCPs, captured 2026-11-14](https://www.linzesshcp.com/linzess-ibs-c-safety#:~:text=2.%20Lacy%20BE%2C%20Pimentel%20M%2C,with%20constipation.%20Gastroenterology.%202022%3B163%281%29%3A118%2D136.%20doi%3A10.1053%2Fj.gastro.2022.04.016)

Note: The recommendation statement is the manufacturer's and cites the ACG clinical guideline (2021) and the AGA clinical practice guideline (2022). The captured page text does not quote either guideline's recommendation or state the grade each guideline assigned.

## Related pages
- [Medical information: Linzess (linaclotide): Irritable bowel syndrome with constipation](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation)
- [Clinical trials](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/safety)
- [Specific populations](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/dosing-and-administration)
